Larsen T A, Teräväinen H, Calne D B
Acta Neurol Scand. 1982 Nov;66(5):547-54. doi: 10.1111/j.1600-0404.1982.tb03141.x.
The beta-1 selective, hydrophilic adrenoceptor blocking drug atenolol (100 mg daily) was compared to the non-selective, lipid-soluble beta-blocker propranolol (240 mg daily), and to placebo, in a double-blind cross-over study in 24 patients with essential tremor. Atenolol and propranolol caused a similar decrease in heart rate. Both beta-blockers also suppressed the tremor intensity; there was no significant difference between them, but both were significantly better than placebo. These drugs did not affect tremor frequency. Twelve of the patients preferred propranolol subjectively, one preferred atenolol and none preferred placebo. No marked side-effects were observed. It was concluded that atenolol and other cardio-selective blockers offer an alternative for patients unable to tolerate the non-selective drugs. The site of action and receptor sub-type involved have still to be determined.
在一项针对24例特发性震颤患者的双盲交叉研究中,将β1选择性、亲水性肾上腺素能受体阻滞剂阿替洛尔(每日100毫克)与非选择性、脂溶性β受体阻滞剂普萘洛尔(每日240毫克)以及安慰剂进行了比较。阿替洛尔和普萘洛尔使心率出现了相似程度的下降。两种β受体阻滞剂均能抑制震颤强度;二者之间无显著差异,但均显著优于安慰剂。这些药物不影响震颤频率。12例患者主观上更喜欢普萘洛尔,1例更喜欢阿替洛尔,无人更喜欢安慰剂。未观察到明显的副作用。得出的结论是,阿替洛尔和其他心脏选择性阻滞剂为无法耐受非选择性药物的患者提供了一种替代选择。其作用部位和涉及的受体亚型仍有待确定。